Original news and analysis on international IP policy
There is an uptick in India-United States relations. US President Barack Obama will be in India in January as the chief guest at the country’s Republic Day Parade. Obama, who hosted India’s new Prime Minister Narendra Modi in Washington in September, will become the first US president to attend such a celebration, a display of India’s military might and ethnic diversity, as well as the first to visit India twice while in office.
Will India’s new government bring in radical changes in the country’s intellectual property rights regime? That question has generated enormous buzz but no definitive answer ever since the Bharatiya Janata Party (BJP) swept to power with a decisive mandate in May this year.
[Update: the Indian government has announced that it has begun a process for a comprehensive IPR policy over the next six months, including a government think tank. See report here. The government website is here.]
New Delhi - On 1 April, in a packed room in India’s Supreme Court, two judges - Justice Aftab Alam and Justice Ranjana Desai - delivered a verdict that has the potential to dramatically change the national and global conversation about patents and patients.
Indian negotiators are reportedly under tremendous pressure to give in to the European demands for a more rigid intellectual property rights regime in the ongoing discussions on EU-India free trade agreement, suggests a leaked draft text of the chapter on IP which is being negotiated.
New Delhi - India’s Intellectual Property Appellate Board (IPAB) today upheld the country’s first compulsory licence on a pharmaceutical product. The much-awaited verdict by Justice (Ms) Prabha Sridevan upholds the compulsory licence issued to Hyderabad-based Natco Pharma Ltd, an Indian generic drug manufacturer, which sells a much cheaper version of German pharmaceutical company Bayer AG's kidney and liver cancer drug Nexavar in the market.
India has started the New Year on a volatile note. With general elections looming in 2014, there is turbulence and not just in the political world. In India’s pharmaceutical industry, there is sparring over the prickly issue of ‘compulsory licenses’, a mechanism by which a government allows a domestic company to manufacture and sell a generic version of a patented drug without the consent of the patent-holder, who receives compensation.
At the ongoing 11th Conference of the Parties (COP11) to the United Nations Convention on Biological Diversity (CBD) in Hyderabad, the hot topic is funds and how to mobilize it. The mega-conference is taking place in the shadow of a global economic slowdown, and delegates gathered at this southern Indian city are most concerned about how to drum up funds to tackle the world’s shrinking biodiversity - the variety of animal and plant life on earth.
NEW DELHI - In this month, there have been two court orders in India that underscore the complexities underlying the country’s intellectual property regime. Last Friday (14 September), the Chennai-based Intellectual Property Appellate Board (IPAB) which is responsible for hearing appeals on patent applications, rejected a petition by German pharma major Bayer AG, seeking a stay on an order of India’s Controller of Patents granting a compulsory licence (CL) to Indian generic drug maker Natco Pharma Limited, for a drug used to treat liver and kidney cancer.
NEW DELHI - The “Nagoya Protocol,” an international agreement struck in the Japanese town of Nagoya in October 2010, has nearly 100 signatory countries, and is a major talking point in the international discourse on biodiversity. But ratification by the governments of these countries remains painfully slow, and the process towards it fraught with daunting challenges, as was evident last week during a key inter-governmental meeting in the Indian capital New Delhi. In an interview with Intellectual Property Watch, the new head of the UN Convention on Biological Diversity had much to say about intellectual property rights.
RIO DE JANEIRO - Many of the technologies that can make the world more sustainable are available today. But how to transfer such green technologies to those most in need of them remains a question on which there are starkly divergent views - even after last week’s much-anticipated Rio+20 leaders’ summit.
As world leaders along with thousands of government, private sector and nonprofit participants, get ready to meet in Rio de Janeiro this week, 20 years after this Brazilian city hosted the historic first Earth Summit, there are fears that there may be no meaningful consensus on how the world can become more liveable and sustainable at the same time. And technology transfer, research and development, intellectual property rights are part of the debate.
The escalating battle between Big Pharma and India’s generic drug manufacturers is pushing down medicine prices in one of the world’s fastest growing pharmaceutical markets.